cell, they are distinct diseases with unique clinicopathologic features. MALT lymphoma is the third most common NHL, representing roughly 8% of all cases. 1 It can arise in a variety of primary sites, including the stomach, ocular adnexa, salivary
Search Results
Gastric MALT Lymphoma Treated With Primary Radiotherapy in the Setting of Autoimmune Disease
Chelsea C. Pinnix, Valerie Reed, and Bouthaina Dabaja
Marginal Zone Lymphoma
Omid S. Shaye and Alexandra M. Levine
mucosa-associated lymphoid tissue B-cell lymphoma . J Clin Oncol 2001 ; 19 : 1600 – 1609 . 14. Ye H Liu H Attygalle A . Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA
Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment
Presented by: Stephen D. Smith
to apply ISRT can yield long-term remissions. Finally, chemoimmunotherapy is reserved for patients with advanced-stage disease or disseminated nodal involvement. Gastric MALT Lymphoma For patients with gastric MALT lymphoma and positive H pylori
Reassessing the Standard of Care in Indolent Lymphoma: A Clinical Update to Improve Clinical Practice
Mathias Rummel
include FL, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and marginal zone lymphoma (MZL), which includes mucosa-associated lymphoid tissue (MALT) lymphoma, splenic MZL, and nodal MZL. 1 Lymphoplasmacytic lymphoma, also termed
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Featured Updates to the NCCN Guidelines
Andrew D. Zelenetz, Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Sven De Vos, Bhagirathbhai Dholaria, Bita Fakhri, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Francisco Hernandez-Ilizaliturri, Eric Hsi, Boyu Hu, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Megan Lim, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, and Hema Sundar
, page 1220). Marginal Zone Lymphomas MZLs originate in the marginal zone of lymphoid follicles found in the mucosa-associated lymphoid tissues (MALT), spleen, and lymph nodes. Extranodal MZLs of MALT (MALT lymphomas), nodal MZL (NMZL), and
Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma
Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo
comorbidity index using physician claims data . J Clin Epidemiol 2000 ; 53 : 1258 – 1267 . 20. Olszewski AJ Castillo JJ . Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER
Non-Hodgkin’s Lymphomas
Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, John C. Byrd, Myron S. Czuczman, Luis Fayad, Andres Forero, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Youn H. Kim, Ann S. LaCasce, Tariq I. Mughal, Auyporn Nademanee, Pierluigi Porcu, Oliver Press, Leonard Prosnitz, Nashitha Reddy, Mitchell R. Smith, Lubomir Sokol, Lode Swinnen, Julie M. Vose, William G. Wierda, Joachim Yahalom, and Furhan Yunus
follows: DLBCL, 31%; follicular lymphoma (FL), 22%; small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), 6%; mantle cell lymphoma (MCL), 6%; peripheral T-cell lymphoma (PTCL), 6%; and mucosa-associated lymphoid tissue (MALT) lymphoma, 5%. The
Non-Hodgkin's Lymphomas
Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nashitha Reddy, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, William G. Wierda, Joachim Yahalom, and Nadeem Zafar
follows: DLBCL, 31%; follicular lymphoma (FL), 22%; small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), 6%; mantle cell lymphoma (MCL), 6%; peripheral T-cell lymphoma (PTCL), 6%; and mucosa-associated lymphoid tissue (MALT) lymphoma, 5%. The